Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.49 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9699251 | 0.79 | HPGD (0.54) | TP53THRBUSP2MAPTHTT | |
| SCHEMBL19851011 | 0.78 | MAPT (0.45) | CTSGCMA1POLBTP53MAPT | |
| SCHEMBL4447502 | 0.77 | CTSG (0.49) | CTSGCMA1POLBTP53MAPT | |
| SCHEMBL4452976 | 0.77 | CTSG (0.49) | CTSGCMA1POLBTP53PDPK1 | |
| SCHEMBL5472178 | 0.73 | TSHR (0.48) | TP53MAPTALDH1A1 | |
| SCHEMBL19771398 | 0.73 | HPGD (0.62) | POLBTP53THRBUSP2MAPT | |
| SCHEMBL12737666 | 0.71 | NPSR1 (0.61) | POLBTP53USP2MAPTHTT | |
| SCHEMBL5622412 | 0.71 | CTSG (0.57) | CTSGCMA1POLBTP53PDPK1 | |
| SCHEMBL18149518 | 0.71 | TSHR (0.55) | POLBTP53MAPTALDH1A1 | |
| SCHEMBL9700228 | 0.70 | ALDH1A1 (0.60) | TP53THRBUSP2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20030083315-A1 | Human chymase inhibitors | TEIJIN LIMITED (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1167360-A9 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1167360-A1 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083315-A1 | Human chymase inhibitors | CMA1, CTRL, CPA4 | CTSG 204/4885CMA1 1/4885POLB 2758/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CTSG 1249/4885CMA1 313/4885POLB 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.